The Indian Pharmaceutical Alliance has approached regulator for a dialogue to understand the concern raised by it
Say heavy penalties for medical errors might raise health care costs and make practitioners too cautious, says Sushmi Dey
As many as 150 applications are stuck at evaluation stage, says official.
Ranbaxy's US factory, Ohm Laboratories, is learnt to have got a clean chit from the American regulator. This US facility was under surveillance of the Food and Drug Administration (FDA) since the end of 2012.
Happy hours, a discount concept popular across bars, restaurants and multiplexes, is now catching up in the health care sector, too.
The country's drug companies have attracted the highest number of enforcements from the American drug regulator in 2013, a year that has seen the US Food and Drug Administration turning stricter to ensure compliance levels and quality of medicines.
DCGI, health ministry initiate dialogues with foreign regulators, try to understand global best practices
The move comes in the wake of many facilities of Ranbaxy in India being barred by the US Food and Drugs Administration for supplying medicines to the US.
Import alert on Ranbaxy's Mohali unit; Strides' injectible arm gets warning letter
Medicines, including antibiotics, contraceptives and anti-diabetic drugs, were found to be out of stock at various places around Delhi.
.jpg)
According to sources, the company has identified smaller markets such as Peru, which do not contribute significantly to profits, where it might shut shop in the near term.
.jpg)
Firms are mandated to change prices of medicines within 45 days of NPPA's notification.
A probe finds several pharma majors in breach of the law; and in turn they blame the government.
.jpg)
The move is expected to delay the introduction of low-priced medicines in the market.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
Face NPPA fine for overcharging on anti-asthma drug
Besides opposing the suspension of three medicines, the sector has also questioned the process adopted by the government.
The latest price revision includes mostly cardiovascular drugs, anti-bacterials, anti-herpes, contraceptives and gastrointestinal medicines
Fearing outbreak of epidemics, the ministry is sending a high level team to review the public health measures in the area
FDA inspectors visited the Mohali plant in the process of giving approval to Ranbaxy's application for Valsartan.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances